Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Legend Biotech Corporation made materially false and/or misleading statements and/or failed to disclose that: On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility. Legend also detailed its struggles with improving manufacturing turnaround times, as well as concerns surrounding the US and non-US price differentials and its ability to penetrate the community settings for its pharmaceutical treatments. Analysts responded to the news with lowered price targets. Following this news, Legend’s stock price fell over 10% to close at $27.80 per share on May 14, 2025.
In order to be eligible to join the LEGN class action lawsuit, you must have incurred a loss on shares of Legend Biotech Corporation purchased during the class period listed above.
TOP
